share_log

eFFECTOR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

eFFECTOR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

eFFECTOR Therapeutics | S-8：員工福利計劃證券登記
美股sec公告 ·  03/28 16:07
Moomoo AI 已提取核心訊息
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on March 28, 2024. The filing pertains to the registration of additional shares for the company's 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan. Specifically, the registration statement covers an additional 500,000 shares of common stock under the 2021 Incentive Award Plan and 100,000 shares under the 2021 Employee Stock Purchase Plan. The company's previous Form S-8 Registration Statement No. 333-260688, related to shares issuable pursuant to these plans, is incorporated by reference into this new filing. eFFECTOR Therapeutics, classified as a non-accelerated filer, smaller reporting company, and emerging growth company, has also included references to its recent financial filings and descriptions of its common stock. The company's leadership, including CEO Stephen T. Worland, Ph.D., and CFO Michael Byrnes, have signed off on the registration statement, affirming the company's compliance with SEC regulations and its commitment to its stock plans.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC) on March 28, 2024. The filing pertains to the registration of additional shares for the company's 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan. Specifically, the registration statement covers an additional 500,000 shares of common stock under the 2021 Incentive Award Plan and 100,000 shares under the 2021 Employee Stock Purchase Plan. The company's previous Form S-8 Registration Statement No. 333-260688, related to shares issuable pursuant to these plans, is incorporated by reference into this new filing. eFFECTOR Therapeutics, classified as a non-accelerated filer, smaller reporting company, and emerging growth company, has also included references to its recent financial filings and descriptions of its common stock. The company's leadership, including CEO Stephen T. Worland, Ph.D., and CFO Michael Byrnes, have signed off on the registration statement, affirming the company's compliance with SEC regulations and its commitment to its stock plans.
生物製藥公司Effector Therapeutics, Inc. 於2024年3月28日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及公司2021年激勵獎勵計劃和2021年員工股票購買計劃的額外股份註冊。具體而言，註冊聲明涵蓋2021年激勵獎勵計劃下的額外50萬股普通股和2021年員工股票購買計劃下的10萬股普通股。該公司先前關於根據這些計劃可發行的股票的S-8表格註冊聲明編號333-260688已納入這份新申報文件中。被歸類爲非加速申報人、小型申報公司和新興成長型公司的Effector Therapeutics還提到了其最近的財務申報和普通股描述。該公司的領導層，包括首席執行官斯蒂芬·沃蘭德博士和首席財務官邁克爾·伯恩斯，已經簽署了註冊聲明，確認了該公司遵守美國證券交易委員會的法規及其對股票計劃的承諾。
生物製藥公司Effector Therapeutics, Inc. 於2024年3月28日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及公司2021年激勵獎勵計劃和2021年員工股票購買計劃的額外股份註冊。具體而言，註冊聲明涵蓋2021年激勵獎勵計劃下的額外50萬股普通股和2021年員工股票購買計劃下的10萬股普通股。該公司先前關於根據這些計劃可發行的股票的S-8表格註冊聲明編號333-260688已納入這份新申報文件中。被歸類爲非加速申報人、小型申報公司和新興成長型公司的Effector Therapeutics還提到了其最近的財務申報和普通股描述。該公司的領導層，包括首席執行官斯蒂芬·沃蘭德博士和首席財務官邁克爾·伯恩斯，已經簽署了註冊聲明，確認了該公司遵守美國證券交易委員會的法規及其對股票計劃的承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息